` SGT (Seagen Inc) vs DAX Index Comparison - Alpha Spread

S
SGT
vs
D
DAX Index

Over the past 12 months, SGT has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +18% growth.

Stocks Performance
SGT vs DAX Index

Loading
SGT
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
SGT vs DAX Index

Performance Gap Between SGT and GDAXI
HIDDEN
Show

Performance By Year
SGT vs DAX Index

Loading
SGT
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Seagen Inc vs Peers

DAX Index
SGT
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Seagen Inc
Glance View

Seagen Inc., nestled in the vibrant Pacific Northwest, has carved out a formidable niche in the biotech arena with its relentless focus on oncology advancements. Born in 1997 as Seattle Genetics, this company has developed a reputation for its pioneering work in antibody-drug conjugates (ADCs). These innovative therapies are designed to deliver potent anti-cancer agents directly to tumor cells, minimizing damage to healthy tissues. Its flagship product, Adcetris, targets various Hodgkin’s lymphomas and has been instrumental in redefining treatment paradigms. This high-caliber development is not just a product of cutting-edge science, but of Seagen's strategic approach to partnerships and collaborations with other pharmaceutical giants, amplifying its research and market reach. Revenue for Seagen doesn't merely stem from its internal product pipeline; it also thrives on strategic alliances and licensing agreements. By engaging in collaborations with leading firms like Pfizer and Takeda, Seagen extends its influence beyond its direct sales, earning substantial sums from milestone payments and royalties as partners bring drugs to market. Furthermore, its business model is deeply entwined with a global vision, where navigating regulatory landscapes across different countries not only expands its market share but also its scientific influence. Seagen’s business strategy is a testament to how innovation in drug delivery mechanisms and thoughtful alliances can coalesce into a formidable presence in the biopharmaceutical industry, fueling both growth and a greater mission in the fight against cancer.

SGT Intrinsic Value
Not Available
Back to Top